BiotechTube

MK-4464 + Pembrolizumab + 89Zr-MK-4464

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced/Metastatic Solid Tumors

Conditions

Advanced/Metastatic Solid Tumors, Neoplasms

Trial Timeline

Sep 25, 2022 → Sep 18, 2025

NCT ID
NCT05514444

About MK-4464 + Pembrolizumab + 89Zr-MK-4464

MK-4464 + Pembrolizumab + 89Zr-MK-4464 is a phase 1 stage product being developed by Merck for Advanced/Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT05514444. Target conditions include Advanced/Metastatic Solid Tumors, Neoplasms.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05514444Phase 1Completed

Competing Products

20 competing products in Advanced/Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
33
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FUEisaiPhase 3
77
PF-05082566 + KW-0761Kyowa KirinPhase 1
33
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)MerckPhase 3
77
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)MerckPhase 1/2
41
Selumetinib + PembrolizumabMerckPhase 1
33
BJ-001 + PembrolizumabMerckPhase 1
33
ADG116MerckPhase 1
33
Gebasaxturev IV + Gebasaxturev ITu + PembrolizumabMerckPhase 2
52
ADU-S100 + ipilimumabNovartisPhase 1
33
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + VinorelbineRochePhase 2
52
Selicrelumab + Vanucizumab + BevacizumabRochePhase 1
33
AMG 510AmgenPhase 1
32
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1PfizerPhase 1/2
40
PF-08046876PfizerPhase 1
32
Capecitabine + SunitinibPfizerPhase 2
51
IBI308Innovent BiologicsPhase 1
32
MM-121 + PaclitaxelSanofiPhase 1
32
Ubamatamab + REGN7075 + SarilumabRegeneron PharmaceuticalsPhase 2
51
ALLO-647 + Fludarabine + CyclophosphamideAllogene TherapeuticsPhase 1
25

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85